Journal
PHARMACEUTICALS
Volume 15, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/ph15030272
Keywords
chemotherapeutic agent; anticancer drugs; isatin derivatives; drug design and development; heterocyclic compounds; therapeutic targeting
Categories
Funding
- University Malaysia Sabah
Ask authors/readers for more resources
Isatin and its derivatives have diverse pharmacological activities and potential as therapeutic agents. Researchers utilize the structure of isatins to design analogues with enhanced biological activity. This review presents the recent developments of isatin analogues from 2016 to 2020 and discusses the structure-activity relationship.
Isatin (1H indole 2, 3-dione) is a heterocyclic, endogenous lead molecule recognized in humans and different plants. The isatin nucleus and its derivatives are owed the attention of researchers due to their diverse pharmacological activities such as anticancer, anti-TB, antifungal, antimicrobial, antioxidant, anti-inflammatory, anticonvulsant, anti-HIV, and so on. Many research chemists take advantage of the gentle structure of isatins, such as NH at position 1 and carbonyl functions at positions 2 and 3, for designing biologically active analogues via different approaches. Literature surveys based on reported preclinical, clinical, and patented details confirm the multitarget profile of isatin analogues and thus their importance in the field of medicinal chemistry as a potent chemotherapeutic agent. This review represents the recent development of isatin analogues possessing potential pharmacological action in the years 2016-2020. The structure-activity relationship is also discussed to provide a pharmacophoric pattern that may contribute in the future to the design and synthesis of potent and less toxic therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available